Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels are reported. Induction therapy consisted of four cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wester, Ruth, van der Holt, Bronno, Asselbergs, Emelie, Zweegman, Sonja, Kersten, Marie Jose, Vellenga, Edo, van Marwijk Kooy, Marinus, de Weerdt, Okke, Minnema, Monique, Lonergan, Sarah, Palumbo, Antonio, Lokhorst, Henk, Broijl, Annemiek, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821616/
https://www.ncbi.nlm.nih.gov/pubmed/30948492
http://dx.doi.org/10.3324/haematol.2018.205476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821616/
https://www.ncbi.nlm.nih.gov/pubmed/30948492
http://dx.doi.org/10.3324/haematol.2018.205476

Ejemplares similares